Lergotrile

Lergotrile (INN, USAN) is an ergoline derivative which acts as a dopamine receptor agonist. It was developed for the treatment of Parkinson's disease, but failed in clinical trials due to liver toxicity.[1][2]

Lergotrile
Clinical data
Other namesLY-79907; 2-Chloro-6-methylergoline-8β-acetonitrile
Identifiers
IUPAC name
  • 2-[(6aR,9S,10aR)-5-chloro-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]acetonitrile
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H18ClN3
Molar mass299.80 g·mol−1
3D model (JSmol)
SMILES
  • CN1C[C@@H](C[C@H]2[C@H]1CC3=C(NC4=CC=CC2=C34)Cl)CC#N
InChI
  • InChI=1S/C17H18ClN3/c1-21-9-10(5-6-19)7-12-11-3-2-4-14-16(11)13(8-15(12)21)17(18)20-14/h2-4,10,12,15,20H,5,7-9H2,1H3/t10-,12-,15-/m1/s1
  • Key:JKAHWGPTNVUTNB-IXPVHAAZSA-N

References
  1. Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M (February 1979). "Lergotrile in Parkinson disease: further studies". Neurology. 29 (2): 267–72. doi:10.1212/wnl.29.2.267. PMID 34808.
  2. Cunningham KA, Callahan PM, Appel JB (July 1984). "Discriminative stimulus properties of lergotrile". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 47–52. PMID 6146709.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.